RecruitingPhase 3NCT06531707

Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine

Efficacy and Safety of Ibuprofen/Loratadine Fixed-dose Combination Versus the Fixed-dose Administration of Monotherapy as Symptomatic Treatment for Patients With the Common Cold

Sponsor

Laboratorios Silanes S.A. de C.V.

Enrollment

177 participants

Start Date

May 20, 2024

Study Type

INTERVENTIONAL

Conditions

Common cold

Summary

Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the drug combination of Ibuprofen/Loratadine versus Ibuprofen versus Loratadine as monotherapy for the symptomatic treatment of the common cold.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ibuprofen, a drug called Ibuprofen + Loratadine fixed dose, and others for people with common cold. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIbuprofen + Loratadine fixed dose

Suspension 8,000 mg / 100 mg / 100 mL, 5 mL twice a day

DRUGIbuprofen

Suspension 2,000 mg / 100 mL, 20 mL twice a day

DRUGLoratadine

Suspension 1 mg / 1 mL, 5 mL twice a day

Locations(1)

Laboratorio Silanes, S.A. de C.V.

Mexico City, Mexico

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06531707

Related Trials

Effects of LP28 on Immunity Enhancement in the Elderly

NCT067241852 locations

A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold

NCT0669788624 locations